scholarly journals Reconstitution of deficient T cell receptor ? chain restores T cell signaling and augments T cell receptor/CD3-induced interleukin-2 production in patients with systemic lupus erythematosus

2003 ◽  
Vol 48 (7) ◽  
pp. 1948-1955 ◽  
Author(s):  
Madhusoodana P. Nambiar ◽  
Carolyn U. Fisher ◽  
Vishal G. Warke ◽  
Sandeep Krishnan ◽  
Jeanne P. Mitchell ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
T Cell ◽  
Cell Signaling ◽  
T Cell Receptor ◽  
Lupus Erythematosus ◽  
Interleukin 2 ◽  
Cell Receptor ◽  
T Cell Signaling ◽  
Systemic Lupus ◽  
Receptor Chain

scholarly journals Fc? receptor type I ? chain replaces the deficient T cell receptor ? chain in T cells of patients with systemic lupus erythematosus

2001 ◽  
Vol 44 (5) ◽  
pp. 1114-1121 ◽  
Author(s):  
Edith J. Enyedy ◽  
Madhusoodana P. Nambiar ◽  
Stamatis-Nick C. Liossis ◽  
Gregory Dennis ◽  
Gary M. Kammer ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
T Cells ◽  
T Cell ◽  
T Cell Receptor ◽  
Lupus Erythematosus ◽  
Cell Receptor ◽  
Receptor Type ◽  
Type I ◽  
Systemic Lupus ◽  
Receptor Chain

scholarly journals MAP4K Family Kinases and DUSP Family Phosphatases in T-Cell Signaling and Systemic Lupus Erythematosus

Cells ◽  
2019 ◽  
Vol 8 (11) ◽  
pp. 1433 ◽  
Author(s):  
Chuang ◽  
Tan
Keyword(s):  
Systemic Lupus Erythematosus ◽  
T Cells ◽  
T Cell ◽  
Cell Signaling ◽  
T Cell Activation ◽  
Lupus Erythematosus ◽  
Cell Activation ◽  
Therapeutic Targets ◽  
T Cell Signaling ◽  
Systemic Lupus

T cells play a critical role in the pathogenesis of systemic lupus erythematosus (SLE), which is a severe autoimmune disease. In the past 60 years, only one new therapeutic agent with limited efficacy has been approved for SLE treatment; therefore, the development of early diagnostic biomarkers and therapeutic targets for SLE is desirable. Mitogen-activated protein kinase kinase kinase kinases (MAP4Ks) and dual-specificity phosphatases (DUSPs) are regulators of MAP kinases. Several MAP4Ks and DUSPs are involved in T-cell signaling and autoimmune responses. HPK1 (MAP4K1), DUSP22 (JKAP), and DUSP14 are negative regulators of T-cell activation. Consistently, HPK1 and DUSP22 are downregulated in the T cells of human SLE patients. In contrast, MAP4K3 (GLK) is a positive regulator of T-cell signaling and T-cell-mediated immune responses. MAP4K3 overexpression-induced RORγt–AhR complex specifically controls interleukin 17A (IL-17A) production in T cells, leading to autoimmune responses. Consistently, MAP4K3 and the RORγt–AhR complex are overexpressed in the T cells of human SLE patients, as are DUSP4 and DUSP23. In addition, DUSPs are also involved in either human autoimmune diseases (DUSP2, DUSP7, DUSP10, and DUSP12) or T-cell activation (DUSP1, DUSP5, and DUSP14). In this review, we summarize the MAP4Ks and DUSPs that are potential biomarkers and/or therapeutic targets for SLE.

T-cell receptor and HLA class II RFLPs in systemic lupus erythematosus

1988 ◽  
Vol 27 (5) ◽  
pp. 392-395 ◽  
Author(s):  
H. Dunckley ◽  
P. A. Gatenby ◽  
S. W. Serjeantson
Keyword(s):  
Systemic Lupus Erythematosus ◽  
T Cell ◽  
T Cell Receptor ◽  
Lupus Erythematosus ◽  
Cell Receptor ◽  
Class Ii ◽  
Hla Class Ii ◽  
Systemic Lupus

Prevalence of T cell receptor ζchain deficiency in systemic lupus erythematosus

Lupus ◽  
2003 ◽  
Vol 12 (1) ◽  
pp. 46-51 ◽  
Author(s):  
M P Nambiar ◽  
J P Mitchell ◽  
R P Ceruti ◽  
M A Malloy ◽  
G C Tsokos
Keyword(s):  
Systemic Lupus Erythematosus ◽  
T Cell ◽  
T Cell Receptor ◽  
Lupus Erythematosus ◽  
Cell Receptor ◽  
Systemic Lupus
Sign in / Sign up

Export Citation Format

Share Document